Limited Target Volume Radiotherapy After Glioblastoma Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: limited-field radiotherapy.
- Who it may be relevant to
- Registry conditions: Glioblastoma (GBM). Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Single-arm Phase II Non-inferiority Clinical Study of Limited Target Volume Radiotherapy After Glioblastoma Surgery
Overview
Research on radiotherapy target volumes for glioblastoma is increasingly focused on exploring more limited yet effective irradiation fields, aiming to achieve local control while minimizing acute and long-term neurotoxicity. Previous retrospective analysis by investigators revealed that local recurrences of glioblastoma are predominantly confined to a narrow margin around the original lesion: 98.3% of recurrences occurred within 0.5 cm of the original T2-FLAIR abnormality, 94.8% within 1 cm of the original T1-enhanced region. These findings have been cited in the ESTRO-EANO treatment guidelines. Building on this evidence, investigators plan to conduct a single-arm, phase II clinical trial to systematically evaluate the efficacy and safety of a 1 cm radiotherapy target volume in post-operative glioblastoma patients.Eligible patients with glioblastoma who have undergone surgical resection will be selected to receive limited-field radiotherapy. The target volume will be defined based on the postoperative MRI enhancing lesion: a 1 cm margin will be added to form the clinical target volume (CTV), followed by a further 0.3 cm margin to create the planning target volume (PTV). A total dose of 60 Gy will be delivered in 30 fractions (2 Gy per fraction, 5 fractions per week). Concurrent and adjuvant chemotherapy will be administered per standard guidelines. The primary efficacy endpoints are the 6-month progression-free survival rate and the incidence of symptomatic radiation-induced brain necrosis of grade 3 or higher. Secondary endpoints include overall survival, patterns of recurrence, neurocognitive function, and quality of life.
Interventions
- Radiation limited-field radiotherapy
limited-field radiotherapy + Concurrent and adjuvant TMZ chemotherapy
Primary outcome measures
- 6m PFS [Time frame: up to 6 month]
- incidence of symptomatic radiation-induced brain necrosis of grade 3 or higher [Time frame: Up to 24 months]
Secondary outcome measures (7)
- OS [Time frame: Up to 24 months]
- Location of first recurrence relative to radiation field (in-field, marginal, or distant) [Time frame: Up to 24 months]
- Cognitive function assessed by Mini-Mental State Examination (MMSE) score [Time frame: Up to 24 months]
- Cognitive function assessed by Montreal Cognitive Assessment (MoCA) score [Time frame: Up to 24 months.]
- Health-Related Quality of Life as assessed by the EORTC QLQ-C30 Global Health Status / QoL scale [Time frame: Up to 24 months]
- Disease-Specific Quality of Life as assessed by the EORTC QLQ-BN20 summary score [Time frame: Up to 24 months]
- Quality of Life as assessed by the FACT-Br Total Score [Time frame: Up to 24 months]
Eligibility criteria
Inclusion criteria
- Aged between 18 and 70 years.
- Diagnosed with glioblastoma by surgical pathology, with the extent of resection achieving maximal safe resection.
- Within 2 to 6 weeks after surgery
- In good physical condition with a Karnofsky Performance Status (KPS) score ≥ 60.
- Hematological, hepatic, and renal functions are essentially normal.
- Signed informed consent, willing to undergo treatment and follow-up as stipulated in the study protocol.
Exclusion criteria
- Prior history of cranial radiotherapy or other malignant tumors.
- Severe dysfunction of vital organs (e.g., heart, liver, kidneys) that precludes tolerance to radiotherapy.
- Active infection, immune system disorders, or other serious chronic diseases.
- Pregnancy or lactation.
- Psychiatric disorders or severe cognitive impairment that compromises the ability to cooperate with treatment and follow-up.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07368283 · 2025ky249